Heart Disease News and Research

Latest Heart Disease News and Research

ACC endorses Emmi Solutions and online patient engagement programs to improve patient communication

When patients hear the words “heart failure” they often remember little of the discussion that follows. Stress, emotions, health literacy and even the patient’s condition itself can create a barrier for good communication between patients and their doctors. Studies show patients forget as much as 80% of their discussion with their doctor by the time they reach the parking garage.

11 Mar 2010

Sleep deprivation may increase heart attack risk

On average, people go to work or school on the first Monday of Daylight Savings after sleeping 40 fewer minutes than normal. And recent studies have found there's a higher risk of heart attacks, traffic accidents and workplace injuries on the first Monday of Daylight Savings.

11 Mar 2010

National freeze on health insurance rates needed

Harvey Rosenfield, author of California's landmark insurance regulation Proposition 103—recognized as the most successful insurance regulation in the country—was joined today by people struggling to pay for health insurance in calling on President Obama and Congress to impose a national freeze on health insurance rates as part of the final round of votes on reform. Consumers must have a breather from yearly premium hikes like the 39% increase planned by Anthem Blue Cross, said Consumer Watchdog, which Rosenfield founded.

11 Mar 2010

Following existing cholesterol-lowering target guidelines can prevent more heart disease-related incidents

Only half of all patients at high risk of heart disease are given correct targets for lowering their cholesterol levels according to a study of 25,250 patients in Germany published online today (Thursday 11 March) in the European Heart Journal.

11 Mar 2010

Lotus Pharmaceuticals announces groundbreaking ceremony to construct new building complex in Beijing

Lotus Pharmaceuticals, Inc., a growing developer and producer of prescription drugs and licensed national seller of pharmaceutical products in the People's Republic of China, reported the groundbreaking ceremony on March 9 to construct a new building complex on the grounds of its production facility in Beijing.

11 Mar 2010

Key stakeholder groups convene to address noncommunicable diseases at Global Forum

The first Global Forum of the Noncommunicable Disease Network (NCDnet) marks the first time WHO has convened key stakeholder groups to address the large-scale and increasing global health and development burden posed by noncommunicable diseases (NCDs).

11 Mar 2010

Poor, minority adults with chronic kidney disease face increase risk of developing ESRD

Chronic kidney disease (CKD) afflicts a large number of younger minority adults receiving medical care in settings that serve the uninsured and underinsured (settings collectively known as the healthcare safety net). Poor, minority adults with moderate to severe CKD are also two to four times more likely to progress to kidney failure than non-Hispanic whites.

11 Mar 2010

Clinical research trial of new treatment to restore brain cells damaged by stroke passes safety stage

A clinical research trial of a new treatment to restore brain cells damaged by stroke has passed an important safety stage, according to the UC Irvine neurologist who led the effort.

11 Mar 2010

Insight Imaging commences operations in partnership with ARA in the Dallas metro-area

InSight Health Services Holdings Corp. announced today that it has commenced operations in partnership with American Radiology Associates, P.A. in the Dallas metro-area. Insight Imaging will manage the partnership, which has acquired ARA’s Willowbend Diagnostic Imaging Center. ARA has also agreed to provide professional services in the coming months at Insight Diagnostic Center – Forest Lane.

11 Mar 2010

Adherence to lipid-lowering guidelines may help reduce cardiovascular deaths

11 Mar 2010

Sleep disorders may increase risk of cardiovascular and metabolic diseases

Many Americans will lose an hour of sleep on March 14, the first day of daylight-saving time, when clocks are set ahead one hour at 2 a.m. local standard time—making it harder to wake up, causing difficulty in staying alert and increasing the chance of sleepy-driving car crashes.

11 Mar 2010

Lincoln, Kucinich weigh in on health bill votes

The Associated Press/The Washington Times: Sen. Blanche Lincoln, D-Ark., "insisted Tuesday she remained opposed to pushing a health care bill through the Senate with a simple majority vote, despite saying she wanted to see what was in the legislation." Lincoln "said those comments didn't represent a change of heart on her stance against the controversial majority-vote procedure known as 'reconciliation.' 'I don't support reconciliation. All I said was I want to see what's in it,' Lincoln told reporters outside the Senate floor. She walked quickly into a senators-only area without elaborating" (Werner, 3/9).

11 Mar 2010

Cardiologists to highlight capabilities of InfraReDx' LipiScan Coronary Imaging System at ACC.10 and i2 Summit

InfraReDx, Inc., an innovative medical device company focused on developing novel diagnostic imaging technologies to accurately identify and characterize diseased intracoronary tissues, today announced that the Company's LipiScan™ Coronary Imaging System will be highlighted in multiple sessions during the 59th Annual Scientific Session of the American College of Cardiology.

11 Mar 2010

Cogent Healthcare, Seton Medical Center to develop exclusive hospitalist care delivery system

Cogent Healthcare today announced a new hospital medicine affiliation with 375-bed Seton Medical Center, located in Daly City, Calif., and the Daly City Hospitalist Medical Group, an existing Seton physician group, to develop a distinctive hospitalist care delivery system.

11 Mar 2010

Lithera announces positive results from Phase IIa clinical study of LIPO-102

Lithera, Inc. today announced positive results from a Phase IIa clinical study of LIPO-102, its novel injectable combination of salmeterol xinafoate (SX) and fluticasone propionate (FP) for selective, non-ablative fat reduction.

11 Mar 2010

HyperBranch Medical Technology's surgical sealants to be marketed under new name – Adherus Surgical Sealants

HyperBranch Medical Technology, Inc. announced today that it will begin to market their surgical sealants under a new product identity – Adherus Surgical Sealants.

11 Mar 2010

Eureka Genomics announces closing of $3.7M private financing round

Eureka Genomics today announced the closing of a $3.7 million private financing round whose participants included private individuals and undisclosed angel investors. The proceeds will further discovery research aimed at identifying novel microorganisms associated with specific cancers and other important diseases, as well as help grow Eureka Genomics’ high-throughput sequencing and bioinformatics service business on a global basis.

11 Mar 2010

Small study shows eprotirome decreases LDL cholesterol

People whose "bad" cholesterol and risk of future heart disease stay too high despite cholesterol-lowering statin therapy can safely lower it by adding a drug that mimics the action of thyroid hormone. In a report published in the Mar. 11, issue of the New England Journal of Medicine, Johns Hopkins and Swedish researchers say an experimental drug called eprotirome lowered cholesterol up to 32 percent in those already on statins, an effect equal to that expected from doubling the statin drug doses, without harmful side effects.

10 Mar 2010

DSPA's lurasidone NDA accepted for FDA review

Dainippon Sumitomo Pharma America, Inc., a U.S. subsidiary of Dainippon Sumitomo Pharma Co., Ltd., today announced that the U.S. Food and Drug Administration recently accepted for review the lurasidone New Drug Application (NDA) for the treatment of patients with acute schizophrenia. The NDA was submitted to FDA on December 30, 2009 and will receive a standard review.

10 Mar 2010

Aastrom Biosciences treats final patient in IMPACT-DCM Phase 2 surgical clinical trial

Aastrom Biosciences, Inc., a leading developer of autologous cellular therapies for the treatment of severe cardiovascular diseases, today reported the final patient treatment in the company's ongoing U.S. Phase 2 surgical clinical trial designated IMPACT-DCM.

10 Mar 2010

Heart Disease News and Research

Latest Heart Disease News and Research

ACC endorses Emmi Solutions and online patient engagement programs to improve patient communication

Sleep deprivation may increase heart attack risk

National freeze on health insurance rates needed

Following existing cholesterol-lowering target guidelines can prevent more heart disease-related incidents

Lotus Pharmaceuticals announces groundbreaking ceremony to construct new building complex in Beijing

Key stakeholder groups convene to address noncommunicable diseases at Global Forum

Poor, minority adults with chronic kidney disease face increase risk of developing ESRD

Clinical research trial of new treatment to restore brain cells damaged by stroke passes safety stage

Insight Imaging commences operations in partnership with ARA in the Dallas metro-area

Adherence to lipid-lowering guidelines may help reduce cardiovascular deaths

Sleep disorders may increase risk of cardiovascular and metabolic diseases

Lincoln, Kucinich weigh in on health bill votes

Cardiologists to highlight capabilities of InfraReDx' LipiScan Coronary Imaging System at ACC.10 and i2 Summit

Cogent Healthcare, Seton Medical Center to develop exclusive hospitalist care delivery system

Lithera announces positive results from Phase IIa clinical study of LIPO-102

HyperBranch Medical Technology's surgical sealants to be marketed under new name – Adherus Surgical Sealants

Eureka Genomics announces closing of $3.7M private financing round

Small study shows eprotirome decreases LDL cholesterol

DSPA's lurasidone NDA accepted for FDA review

Aastrom Biosciences treats final patient in IMPACT-DCM Phase 2 surgical clinical trial

Unlocking drug amorphization: Continuous, solvent-free twin screw granulation

How can super-resolution technology help study neurotransmission?

The Proteoform Puzzle: Unlocking the Next Frontier

Heart Disease News and Research

Latest Heart Disease News and Research

Unlocking drug amorphization: Continuous, solvent-free twin screw granulation

How can super-resolution technology help study neurotransmission?

The Proteoform Puzzle: Unlocking the Next Frontier

Newsletters you may be interested in